Related Articles Biopharma Funds Surge on Deals and Drug Breakthroughs Stephen Taub PivotalPath: Hedge Funds Post One of Their Best First Halves in Nearly Three Decades The Editorial Team Capital Markets, Reframed: A Corporate Defined Benefit Perspective Sponsored by Fidelity Investments